 |
|
| |
Biogen Idec is principally engaged in developing, manufacturing and marketing medications for human healthcare and is committed to the pursuit of new standards of care in dermatology, neurology and oncology through its pioneering research in these fields. Biogen Idec's current strategy is to research, develop, manufacture, and market its own products, as it has with AMEVIVETM (alefacept), Canada’s first and only biological treatment indicated for moderate to severe chronic plaque psoriasis. Currently there are several medications in the dermatology, neurology and oncology areas that have been submitted to health authorities or will be submitted over the next few years. In addition, Biogen Idec has several pre-clinical & Phase 1/2 programs in development. Biogen Idec has over 4000 employees worldwide, operates in 17 countries and its products are now available in over 100 nations. Biogen Idec Canada’s research and development activities are focused on novel products that meet the needs of physicians and patients in the dermatology and neurology therapeutic areas. Biogen Idec Canada is headquartered in Mississauga, Ontario and is one of Canada’s fifty largest biopharmaceutical companies. The company is traded on the NASDAQ exchange under the trading symbol BIIB. Biogen Idec is Transforming Discovery into Care.
Click here to close this window
|
